A Phase II Randomized, Placebo-Controlled Study of GBT440 to Evaluate the Safety, Tolerability, Pharmacokinetics and Effect on Hypoxemia in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Phase of Trial: Phase II
Latest Information Update: 12 Apr 2017
At a glance
- Drugs GBT 440 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; Proof of concept
- Sponsors Global Blood Therapeutics
- 14 Sep 2016 According to a Global Blood Therapeutics media release, data from this trial are expected in the second half of 2017.
- 05 Apr 2016 New trial record
- 29 Mar 2016 According to a Global Blood Therapeutics media release, this trial is expected to start in 2016.